Guillain-Barré Syndrome Presenting as Pseudo-Cerebellar Syndrome: A Case Report from a Resource-Limited Setting in Sub-Saharan Africa Guillain-Barré Syndrome (GBS) is the most frequent cause of acute ...

Hansa Biopharma, “Hansa”, today announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that demonstrated imlifidase was safe and well tolerated when administered prior to standard of ...

Thanks to the relentless efforts of medical researchers around the world, several different messenger ribonucleic acid (mRNA) and vector-based vaccines were authorized for use by regulatory bodies ...

The FDA granted Pfizer a breakthrough therapy designation for its group B Streptococcus vaccine candidate for pregnant people to prevent GBS disease in newborns based on its ongoing phase 2 trial. GBS ...

Annexon Biosciences CEO Doug Love considers Guillain-Barré syndrome — also known as GBS — to be the “most unique disease” he’s worked on in 25 years in biotech because of its sudden onset. A rare ...